Ultragenyx's Crysvita scores FDA nod in 2nd ultra-rare bone disorder

Ultragenyx and Kyowa Kirin raised eyebrows when they launched ultra-rare disease Crysvita in 2018 with an eye-popping price tag of $200,000 per year. Despite some pushback from cost watchdogs, the partners kept pushing to expand Crysvita's reach and now have the FDA's green light in a second indication.